The Brussels International Declaration on Lipoprotein(a) Testing and Management

Area of Science:

• Cardiovascular Medicine
• Public Health Policy
• Genetic Risk Factors

Background:

• Elevated lipoprotein(a) [Lp(a)] is a significant, independent, and causal risk factor for cardiovascular disease.
• Current Lp(a) testing rates are critically low (1-2%), despite 20% of the population having elevated levels.
• This disparity highlights a gap in cardiovascular risk assessment and preventative strategies.

Purpose of the Study:

• To address the low rates of lipoprotein(a) [Lp(a)] testing and management globally.
• To advocate for policy changes and increased awareness regarding Lp(a) as a cardiovascular risk factor.
• To foster a coordinated international effort for Lp(a) testing and management.

Main Methods:

• Convening the Lp(a) Global Summit in Brussels, Belgium (March 24-25, 2025).
• Co-creation of the Brussels International Declaration on Lp(a) Testing and Management by the Lp(a) International Task Force and global leaders.
• Collaboration with scientific organizations, patient advocacy groups, and policymakers.

Main Results:

• The Brussels Declaration outlines five key calls to action for improving Lp(a) testing and management.
• These include integrating Lp(a) into cardiovascular health plans, investing in targeted programs, mandating systematic testing, incorporating results into risk assessments, and enhancing education.
• The declaration emphasizes the cost-saving potential of proactive Lp(a) management.

Conclusions:

• Systematic, reimbursed, and lifelong lipoprotein(a) [Lp(a)] testing is essential for cardiovascular disease prevention.
• Policy integration, investment, and education are crucial for effective Lp(a) management.
• Addressing elevated Lp(a) levels can significantly reduce cardiovascular risk and healthcare costs.